Georgia Medical Cannabis Expansion: What Changes on July 1, 2026 Under SB 220

On May 12, 2026, Governor Brian Kemp signed Senate Bill 220, the Putting Georgia's Patients First Act, into law. The bill takes effect statewide on July 1, 2026, and represents the most significant restructuring of Georgia's medical cannabis program since it was created in 2015.

For more than a decade, Georgia has run one of the most restrictive medical cannabis programs in the country. Patients were capped at 5% THC, denied vaporization, blocked from access unless their condition was "severe" or "end-stage," and forced to navigate a registry that the law itself refused to call "medical cannabis." All of that changes on July 1.

This article walks through every meaningful change in SB 220, side by side with the program patients have been working under since 2019, and explains what each shift means for current patients, new applicants, physicians, and out-of-state travelers.

If you live in Georgia and want to skip straight to getting evaluated, learn how to get a Georgia medical marijuana card including eligibility, pricing, and the telehealth process.

The Headline Changes at a Glance

Provision	Old Program (Pre-July 1)	New Program (Effective July 1, 2026)
Legal name in state code	"Low THC oil"	"Medical cannabis"
THC potency cap	5% maximum (with CBD ≥ THC requirement)	No percentage cap
Possession limit	20 fluid ounces of low THC oil	12,000 mg cumulative THC, with 1,200 mg per labeled package
Allowed product forms	Oils, tinctures, capsules, lozenges, topicals, transdermal patches	All prior forms plus vape cartridges and concentrates (subject to commission rulemaking)
Smoking	Prohibited	Still prohibited
Vaporization	Prohibited	Allowed for patients 21 and older, private settings only
Severity requirement	Many conditions required a "severe" or "end-stage" diagnosis	Severity language eased on several conditions; commission rulemaking will finalize scope
New qualifying conditions	Closed list	Adds lupus; expands cancer eligibility, renames Crohn's to inflammatory bowel disease, renames AIDS to HIV Stage III; tightens intractable pain definition
Out-of-state reciprocity	None	45 days for visiting registered patients with valid out-of-state cards
Card validity	5 years (extended in Oct 2024)	5 years from date of issuance, retained under SB 220
Annual recertification	Required for all patients	Eliminated for patients with incurable or irreversible conditions
Production facility siting	Existing zoning rules	At least 3,000 feet from any school or church
Licensee penalties	Existing framework	Tiered fines up to $25,000 (first), $50,000 (uncorrected), $75,000 (subsequent)
Program oversight	Georgia Access to Medical Cannabis Commission	Same commission, with expanded authority including seed-to-sale tracking

The rest of this article unpacks each of these in detail.

"Medical Cannabis" Replaces "Low THC Oil"

The first change is linguistic, but it matters more than it sounds. Since 2015, Georgia has officially regulated a substance called "low THC oil." That term wrote out tinctures, capsules, transdermal patches, and lotions on paper even after 2021's SB 195 added them as legal formats, and it locked the entire program into a 5% THC ceiling.

SB 220 strikes "low THC oil" from the relevant state statutes and replaces it with "medical cannabis." The change cascades through Georgia's controlled substances framework, the Department of Public Health's registry rules, and the Georgia Access to Medical Cannabis Commission's product oversight authority. It also brings Georgia in line with how the other 40 states with medical programs describe their products.

The Marijuana Policy Project now classifies Georgia as a comprehensive medical cannabis state as a direct result of this change, a status the program had been denied for the entirety of its decade-long history.

Qualifying Conditions: What's Added, What's Eased

Before July 1, Georgia's qualifying conditions list looked stingy on paper and even stingier in practice. Cancer, multiple sclerosis, Parkinson's disease, Alzheimer's, ALS, AIDS, autism spectrum disorder, sickle cell disease, Crohn's disease, mitochondrial disease, Tourette's syndrome, and a handful of others were technically listed, but most were tagged with a "severe" or "end-stage" requirement. Patients with early or mid-stage diagnoses were locked out by design.

SB 220 attacks the list from two angles: it adds new conditions, and it surgically updates existing ones.

Conditions Added or Expanded Under SB 220

• Lupus (systemic lupus erythematosus). Wholly new addition. Reflects years of patient testimony on inflammation, fatigue, and chronic pain.
• Inflammatory bowel disease (IBD). Broader than the prior Crohn's-only allowance; now covers ulcerative colitis as well.
• HIV Stage III. Replaces the older AIDS-only access language with a clearer, earlier-stage federal staging threshold.
• Cancer eligibility. Broadened to "any cancer except non-metastatic skin cancer." A patient with an early-stage cancer diagnosis no longer has to wait for the disease to progress to register.
• Intractable pain. Confirmed in statute with a strict 6-month failed-treatment definition. This is already the most common qualifying condition in the program and was previously vulnerable to administrative narrowing.

Severity Language: What Changed and What Didn't

The cancer expansion above is the most consequential severity-language change in the bill: cancer no longer requires an "end-stage" or wasting-syndrome finding. The intractable pain definition was also clarified, replacing administrative ambiguity with a black-letter 6-month threshold.

Other conditions still carry severity qualifiers in the statute as enacted. Patients with multiple sclerosis, Parkinson's disease, ALS, Alzheimer's, sickle cell disease, peripheral neuropathy, and Tourette's syndrome should expect the program's existing severity framing to continue applying. The Georgia Access to Medical Cannabis Commission's rulemaking through the rest of 2026 will determine exactly where the new lines land.

The practical effect of the changes that did pass is large. Industry observers and the bill's sponsors have suggested the eligible patient pool could grow into the hundreds of thousands once these expansions are fully implemented, up from approximately 34,500 registered patients at the time the bill was signed. Exact projections vary, but every analysis points to a multi-fold expansion.

If you previously applied and were denied because your condition was not classified as severe, or because cancer eligibility required end-stage disease, you should reapply after July 1. The Georgia medical marijuana card page covers the updated eligibility framework in detail.

The 12,000 mg Possession Limit (and the End of the 5% Cap)

The old THC potency rule was the single most criticized feature of Georgia's program. By restricting products to no more than 5% THC, with a CBD-balance requirement that CBD content equal or exceed THC, the state effectively forced patients to dose with diluted oils that contained 500 to 900 mg of total THC per bottle. For a patient with chronic pain or severe PTSD, that often was not enough medicine to last more than a few weeks even with strict dosing.

SB 220 replaces the percentage cap with two milligram-based limits:

• A cumulative possession limit of 12,000 milligrams of total THC, provided products are kept in their labeled pharmaceutical containers.
• A per-package cap of 1,200 milligrams of THC. No single product can exceed this on the package label.

There is no longer a ceiling on the concentration of any individual product. A few implications worth pulling apart:

• Higher-potency oils, tinctures, vape cartridges, and concentrates become legally manufacturable. Georgia's licensed cultivators can now produce full-strength formulations comparable to what is sold in Florida or Pennsylvania, within the per-package mg cap.
• Patients dose by milligram, not by percentage. Physicians and dispensary consultants will need to recalibrate counseling around mg-per-dose rather than percentage strength.
• The 12,000 mg cap is generous. For context, 12,000 mg works out to roughly 600 servings at 20 mg each, or several months of moderate-dose chronic-pain treatment. A typical patient using oils for daily symptom management is unlikely to brush against the cap.
• Pharmaceutical packaging requirements stay. Products must remain in labeled containers with the THC content clearly stated. This is what keeps the new possession framework workable for law enforcement.

Vaporization Is Now Legal (With Conditions)

For the first time, Georgia patients have access to inhaled medical cannabis. SB 220 authorizes vaporization for patients aged 21 and older, with three significant constraints:

1. Smoking remains prohibited. Lighting a joint, blunt, or pipe is still outside the law's protection. Combustion of cannabis plant material is not authorized under any reading of the bill.
2. Public consumption is prohibited. Vaporization must take place in a private setting. Workplaces, schools, restaurants, parks, public transit, and other public spaces remain off-limits regardless of patient or caregiver status.
3. Vape cartridges and concentrates are now authorized products. Patients 21 and over can purchase oil-format vape cartridges and concentrate formats designed for vaporization devices. The status of dry-herb or "leaf marijuana" vaporization formats remains an open rulemaking question (covered below).

The 21-and-over restriction reflects a compromise that emerged during House negotiations. Patients between 18 and 20, and qualifying pediatric patients, retain access to all other product formats: oils, tinctures, capsules, lozenges, topicals, and transdermal patches.

Industry executives and physician advocates have publicly called vaporization the single most patient-relevant change in the bill. Inhaled cannabis reaches the bloodstream within minutes, which matters for breakthrough pain, acute nausea, and seizure clusters where oils and capsules act too slowly. For a veteran experiencing a PTSD panic episode or a cancer patient with acute nausea who can't hold down oral medication, that pharmacokinetic difference is the difference between relief and continued suffering.

Edibles, Gummies, and "Vaporized Flower": The Ambiguity

Multiple sources reviewing the final bill text report that SB 220 expands the types of products dispensaries can sell to include some form of vaporized cannabis. The bill also revises the prior list of prohibited product categories.

A note of caution is in order. Several specialist legal and dispensary-side analyses read the enacted bill as continuing to prohibit conventional edible food products (cookies, brownies, candies, baked goods, beverages), with lozenges as the established exception. Gummies in particular sit in an interpretive gray zone: the word "edibles" was revised in the statute, but the residual "food products" prohibition may still exclude conventional gummies. The same ambiguity applies to dry-herb or "leaf marijuana" vaporization formats versus oil-only vape cartridges.

The Georgia Access to Medical Cannabis Commission has until January 1, 2027 to finalize testing, packaging, and ingestion rules for the new formats, and that rulemaking will determine exactly which products clear the bar. Patients should expect tinctures, capsules, and oil-format vape cartridges to arrive at dispensaries before any solid-edible products do, and any gummy or dry-herb format that does reach shelves will land later in 2026 or in 2027 once the commission's rules are final.

Out-of-State Reciprocity: A 45-Day Window

Before SB 220, Georgia recognized no other state's medical cannabis cards. A patient flying in from Florida, Pennsylvania, or California with a legitimate medical card could be arrested for simple possession.

SB 220 creates a 45-day reciprocity window. Out-of-state registered patients with a valid medical cannabis card from another state can lawfully possess medical cannabis in Georgia for up to 45 days, provided:

• They have not established residence in Georgia for more than 45 days.
• Products are kept in their original, labeled pharmaceutical packaging.
• The 12,000 mg cumulative possession limit still applies.
• All consumption restrictions (no smoking, no public use, 21+ for vaporization) apply.

Reciprocity does not extend purchase rights. Visiting patients cannot buy from a Georgia dispensary or authorized pharmacy using an out-of-state card. They can only possess and consume medicine they brought with them.

This is a meaningful change for the millions of medical cardholders who travel to Atlanta for work, attend conferences, visit family, or transit through Hartsfield-Jackson, the busiest airport in the country.

Physician Changes: 5-Year Cards, Recertification Exemptions, and Telehealth

SB 220 includes several physician-side and patient-side provisions that will reshape how Georgia patients access certification.

Registration cards remain valid for 5 years. SB 220 retains the 5-year card validity framework that was already in place after the October 2024 extension. There is no rollback to annual cards.

Annual recertification eliminated for permanent conditions. Patients whose qualifying condition has been classified by their physician as incurable or irreversible are entirely exempt from recurring certification requirements within the 5-year card window. For someone with MS, Parkinson's, ALS, or terminal cancer, that change alone saves hundreds of dollars in repeat physician fees over the life of the card.

Telemedicine remains available with Georgia-licensed physicians. Patients in Georgia can complete the evaluation by video with a Georgia-licensed MD or DO. Schedule with Georgia medical marijuana doctors who certify under the updated framework.

Electronic registration cards are now authorized. Patients and caregivers may elect a physical card, an electronic card, or both. Electronic cards are designed to allow immediate purchase upon receipt of an eligible application, eliminating the multi-week UPS wait for a mailed card. The electronic-card rollout is subject to DPH implementation, with full implementing rules due January 1, 2027.

See the Georgia medical marijuana card renewal page for how the 5-year validity period and recertification exemptions work in practice for current patients.

The Georgia Access to Medical Cannabis Commission Gets More Power

The commission that oversees the program receives expanded authority under SB 220, including:

• Operating a comprehensive seed-to-sale tracking system for all medical cannabis cultivated, processed, and sold in Georgia.
• Studying and publishing best practices for medical cannabis treatment.
• Coordinating directly with state public health officials on patient outcomes.
• Setting testing and packaging rules for the new product formats authorized by SB 220.
• Conducting public-awareness activities regarding effective medical cannabis use.
• Levying tiered civil fines against licensees that fail to follow commission rules: $25,000 for a first offense, $50,000 if the violation is not remedied within 60 days, and $75,000 for subsequent offenses. The commission may also order a licensee to cease operations for up to 30 days after a third notice.

SB 220 also requires medical cannabis production facilities to be located at least 3,000 feet from any school or church, which will constrain where new dispensary or processing operations can be sited. The Department of Public Health must issue full implementing rules for the SB 220 framework by January 1, 2027. Patients should expect full-strength oils, tinctures, and oil-format vape cartridges to begin arriving at dispensaries through the summer and fall of 2026, with the full slate of new offerings available by early 2027 as commission rulemaking concludes.

What Happens to Current Patients on July 1?

If you already hold a valid Georgia low THC oil registration card, your card remains valid. It automatically converts to a Medical Cannabis Patient Registry card under the renamed program. You do not need to reapply, re-pay, or re-certify because of SB 220. When it does come time to renew your Georgia medical marijuana card, the new framework will apply.

What changes for you, in practice:

• You can purchase higher-potency products as soon as licensed producers manufacture and label them under the new mg-per-package rules.
• If you are 21 or older, you can purchase vape cartridges and concentrate formats once dispensaries have them in stock.
• Your renewal cycle remains five years (already extended in October 2024).
• If your physician classifies your condition as incurable or irreversible, you are exempt from annual recertification.
• If you previously held back from applying because your condition did not meet the "severe" threshold, you may now qualify under the revised cancer eligibility, the new lupus listing, the broader IBD definition, the HIV Stage III rename, or the clarified intractable-pain framework.

Caregivers who hold a registry card already see no change to their card on July 1; the same convert-and-keep-valid rule applies.

What New Patients Should Do

If you have a qualifying condition under the expanded list, the process is straightforward:

1. Confirm eligibility. Review the updated qualifying conditions and gather any relevant medical records.
2. Get evaluated by a Georgia-licensed physician. Telemedicine evaluations are available with a Georgia-licensed MD or DO. Schedule with Georgia medical marijuana doctors who certify under the SB 220 framework.
3. Register with the state. After your evaluation, your physician submits your information to the Medical Cannabis Patient Registry (the renamed Low THC Oil Patient Registry).
4. Pay the $30 state fee. Cards are valid for 5 years from issuance.
5. Visit a licensed dispensary or authorized pharmacy. Georgia has approximately 75 access points statewide, including 19 Commission-licensed dispensaries plus independent pharmacies authorized to dispense medical cannabis.

How SB 220 Compares to Georgia's Last Three Expansions

Georgia's medical program has expanded three times before in any material way. SB 220 dwarfs all of them.

• 2017 (SB 16). Added six conditions including autism, AIDS, Tourette's syndrome, and Alzheimer's. Most additions came with severity restrictions. Patient possession limit set at 20 fluid ounces of low THC oil.
• 2019 (Georgia's Hope Act, HB 324). Authorized six in-state cultivators and created the Georgia Access to Medical Cannabis Commission. Did not change qualifying conditions or potency limits.
• 2021 (SB 195). Expanded legal product formats beyond oils to include tinctures, transdermal patches, lotions, and capsules. Kept the 5% THC cap.
• 2026 (SB 220). Renamed the program, eliminated the percentage cap, authorized vaporization, expanded conditions, eased severity language on cancer and intractable pain, added 45-day reciprocity, locked in the 5-year card with an incurable/irreversible recertification exemption, and restructured commission authority.

Every prior expansion was incremental. SB 220 is a rewrite.

The Politics Around the Signing

SB 220 cleared both chambers of the Georgia General Assembly with bipartisan supermajorities. Senate sponsor Sen. Matt Brass (R-Newnan) built the bill on the recommendations of the 2025 House Blue Ribbon Study Committee on Medical Marijuana and Hemp Policies, chaired by physician-legislator Rep. Mark Newton (R-Augusta).

Floor amendments to weaken the bill failed repeatedly during the Senate debate. Attempts to lower the THC cap, to remove vaping, and to strip PTSD and intractable pain from the qualifying conditions list were all defeated by wide margins, signaling durable bipartisan support for expansion.

In his signing statement, Governor Kemp acknowledged reservations about cannabis policy generally while emphasizing that the bill is strictly a medical measure. He noted that medical cannabis "provides significant relief to symptoms that would otherwise go untreated or would be treated with even more harmful opioids," and explicitly separated the medical program from any question of recreational legalization.

A group of medical professionals had urged the governor to veto the bill, citing concerns about higher-potency products and inhalation-related risk. Supporters, including the major in-state cultivators and patient advocacy groups, countered that the program's existing restrictions were forcing patients toward unregulated hemp products and the illicit market.

Open Questions Heading Into July 1

A few items remain in flux as of late May 2026:

• Final vaporizer hardware rules. The commission will set technical standards for what constitutes an authorized vaporization device.
• Edible and dry-herb scope. Which specific gummy or vaporizer-flower categories will clear the commission's rulemaking, and whether traditional food-product items like cookies and candies remain prohibited under the residual "food products" carve-out.
• Electronic card rollout timeline. The law authorizes digital registration cards but does not specify when the Department of Public Health will complete the transition.
• Dispensary expansion. Whether the state will authorize additional Commission-licensed dispensary locations now that the eligible patient pool may grow significantly.
• Insurance and employment. Georgia employers retain broad authority over workplace cannabis policies. SB 220 does not create employment protections for registered patients.

We will update this article as the Georgia Access to Medical Cannabis Commission publishes its rulemaking decisions through the rest of 2026 and into 2027.

The Bottom Line

July 1, 2026 turns Georgia from one of the most restrictive medical cannabis states in the country into a functional, modern medical program. The renaming, the potency overhaul, vaporization access for adults, expanded conditions, the cancer-eligibility broadening, 5-year cards with a recertification exemption, and 45-day reciprocity together mark the largest single shift in Georgia cannabis policy since the program was created.

If you live in Georgia and have a condition that may qualify under the expanded list, or if you were previously denied because your diagnosis was not classified as severe, the smart move is to get evaluated now so your card is ready when the new products reach dispensary shelves in July.

Learn how to get a Georgia medical marijuana card including eligibility, pricing, and how to get evaluated via telehealth with a Georgia-licensed physician.

---

Georgia Medical Cannabis Resources:

• Get Your Georgia Medical Cannabis Card
• Find a Georgia MMJ Doctor
• Georgia Qualifying Conditions
• Georgia Medical Cannabis Card Renewals
• Georgia Caregivers
• Georgia Marijuana Laws
• Georgia SB 220: Full Legal Analysis

---

Sources

• Georgia Senate Bill 220 (2026), "Putting Georgia's Patients First Act" (Act 712), signed May 12, 2026
• Office of Governor Brian Kemp, signing statement, May 12, 2026
• FOX 5 Atlanta, "Georgia medical cannabis bill signed into law," May 13, 2026
• Marijuana Moment, "Georgia Governor Signs Bill To Expand Medical Marijuana Access," May 13, 2026
• Marijuana Policy Project, Georgia state policy summary
• BillTrack50, GA SB 220 detail and vote history
• NORML, Georgia expansion analysis
• Georgia Recorder and Capitol Beat, legislative reporting on Senate and House passage
• Cannabis Business Times, Marijuana Herald, and Cannabis Law Journal analysis of the enacted text